[ad_1]





According to a paper by Miljković et al. (2023), the answer is ‘no‘. The authors examine oncology treatments with FDA approvals between 2015 and 2020 and identify average wholesale prices from Redbook. Drugs were classified into three categories: (i) first approval of a new mechanism of action compound, (ii) next-in-class approval regardless the tumor type, and (iii) subsequent approval of the same drug. Using this approach, they found that:

There were 224 cancer drug approvals across 119 individual drugs, with a median annual cost of $196 000 (IQR, $170 000-$277 000). Gene and viral therapies were the most expensive (median, $448 000 [IQR, $448 000-$479 000]), followed by small molecule therapy (median, $244 000 [IQR, $203 000-$321 000), and biologics (median, $185 000 [IQR, $148 000-$195 000]). There was no significant difference in cost between first-in-class, next-in-class, and subsequent approvals of an already approved drug.

The full article is here.



[ad_2]

Source link

Leave a Reply

Explore More

Amoxicillin in short supply amid jump in RSV cases

[ad_1] Pharmacies, hospitals and manufacturers are reporting a shortage of the popular antibiotic amoxicillin, a situation experts attribute to the approaching cold and flu season and an increasing number of

The wonky Medicare proposal worrying safety-net hospitals

[ad_1] Hospitals in some states that haven’t expanded Medicaid coverage worry a proposed Centers for Medicare and Medicaid Services policy could deprive them of hundreds of millions of dollars in

(We Don’t) Trust The Science – The Health Care Blog

[ad_1] By KIM BELLARD I know the A.I. community is eagerly waiting for me to weigh in on the Sam Altman/OpenAI dramedy (🙄), but I’m not convinced this isn’t all